Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).
Status:
Terminated
Trial end date:
2019-10-22
Target enrollment:
Participant gender:
Summary
The PULSAR trial is an international, investigator-initiated, single arm open-label phase II
study. The aim of this study is to measure the clinical activity of the combination
FOLFIRI-aflibercept in an homogeneous group of patients with metastatic colorectal cancer,
and treated with a FOLFIRI-aflibercept regimen as first line treatment.